VIDEO: Recognizing imaging, patient characteristics important for GA management
Click Here to Manage Email Alerts
ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Aleksandra Rachitskaya, MD, gives a broad overview of geographic atrophy management in the clinic now that treatments have become available.
One of the challenges comes from the fact that patients recruited in clinical trials do not represent the whole spectrum of patients in clinical practice, and it is hard to decide how to apply safety and efficacy data. In addition, geographic atrophy (GA) is probably underestimated in terms of numbers because GA is undercoded, as shown by many studies.
She also speaks about the importance of recognizing the factors, in terms of imaging and patient characteristics, that lead to progression from intermediate age-related macular degeneration to GA and progression of GA in these patients. In this, AI will play an important role.
Finally, she speaks about treatment and the problem of incorporating into clinical practice the knowledge acquired from the studies on the two drugs now available. It is tempting to compare the drugs, but it is almost impossible because the study designs were different, Rachitskaya said.
Collapse
Rachitskaya A. Real world experience in GA therapy and patient selection. Presented at: FLORetina-ICOOR; Nov. 30-Dec. 3, 2023; Rome.
Read more about
Click Here to Manage Email Alerts